These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 28823747

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. 18F-FDG-PET in Finnish patients with clinical suspicion of cardiac sarcoidosis: Female sex and history of atrioventricular block increase the prevalence of positive PET findings.
    Tuominen H, Haarala A, Tikkakoski A, Korkola P, Kähönen M, Nikus K, Sipilä K.
    J Nucl Cardiol; 2019 Apr; 26(2):394-400. PubMed ID: 28585031
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis.
    Mc Ardle BA, Leung E, Ohira H, Cocker MS, deKemp RA, DaSilva J, Birnie D, Beanlands RS, Nery PB.
    J Nucl Cardiol; 2013 Apr; 20(2):297-306. PubMed ID: 23288545
    [Abstract] [Full Text] [Related]

  • 46. Diagnosis and Detection of Myocardial Injury in Active Cardiac Sarcoidosis--Significance of Myocardial Fatty Acid Metabolism and Myocardial Perfusion Mismatch.
    Momose M, Fukushima K, Kondo C, Serizawa N, Suzuki A, Abe K, Hagiwara N, Sakai S.
    Circ J; 2015 Apr; 79(12):2669-76. PubMed ID: 26477356
    [Abstract] [Full Text] [Related]

  • 47. Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging.
    Bravo PE, Raghu G, Rosenthal DG, Elman S, Petek BJ, Soine LA, Maki JH, Branch KR, Masri SC, Patton KK, Caldwell JH, Krieger EV.
    Int J Cardiol; 2017 Aug 15; 241():457-462. PubMed ID: 28318664
    [Abstract] [Full Text] [Related]

  • 48. Regional myocardial damage and active inflammation in patients with cardiac sarcoidosis detected by non-invasive multi-modal imaging.
    Kataoka S, Momose M, Fukushima K, Serizawa N, Suzuki A, Kondo C, Abe K, Sakai S, Hagiwara N.
    Ann Nucl Med; 2017 Feb 15; 31(2):135-143. PubMed ID: 27804054
    [Abstract] [Full Text] [Related]

  • 49. Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: The effect of a structured patient preparation protocol.
    Christopoulos G, Jouni H, Acharya GA, Blauwet LA, Kapa S, Bois J, Chareonthaitawee P, Rodriguez-Porcel MG.
    J Nucl Cardiol; 2021 Apr 15; 28(2):661-671. PubMed ID: 31111450
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Fasting FDG PET compared to MPI SPECT in cardiac sarcoidosis.
    Brancato SC, Arrighi JA.
    J Nucl Cardiol; 2011 Apr 15; 18(2):371-4. PubMed ID: 21318450
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. (18)F-FDG PET/CT for the assessment of myocardial sarcoidosis.
    Skali H, Schulman AR, Dorbala S.
    Curr Cardiol Rep; 2013 May 15; 15(5):352. PubMed ID: 23504346
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.